## UNITED STATES SECURITIES AND EXCHANGE COMMISSION December 7, 2017

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

## **Denali Therapeutics, Inc.**

## File No. 333-221522 - CF#35583

Denali Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on November 13, 2017.

Based on representations by Denali Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.10	through October 27, 2027
Exhibit 10.11	through October 27, 2027
Exhibit 10.12	through September 6, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary